Continuous Intravenous Infusion of High-dose Recombinant Interleukin-2 for Acute Myeloid Leukaemia--a Phase II Study

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1992 Jan 1

PMID 1540980

Citations 11

Authors

S H Lim

A C Newland

S Kelsey

A Bell

E Offerman

C Rist

D Gozzard

D Bareford

M P Smith

A H Goldstone

Affiliations

Soon will be listed here.

Abstract

A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation.

Citing Articles

Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.

Siemiatkowska A, Bryl M, Kosicka-Noworzyn K, Tvrdon J, Golda-Gocka I, Glowka F Cancer Immunol Immunother. 2023; 72(6):1853-1863.

PMID: 36688998 PMC: 9870198. DOI: 10.1007/s00262-023-03377-8.

Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy.

Bendickova K, Fric J J Leukoc Biol. 2020; 108(1):427-437.

PMID: 32480431 PMC: 7384134. DOI: 10.1002/JLB.5MIR0420-055R.

Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Gavalas N, Karadimou A, Dimopoulos M, Bamias A Clin Dev Immunol. 2011; 2010:791603.

PMID: 21318181 PMC: 3034919. DOI: 10.1155/2010/791603.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Baer M, George S, Caligiuri M, Sanford B, Bothun S, Mrozek K J Clin Oncol. 2008; 26(30):4934-9.

PMID: 18591543 PMC: 2652081. DOI: 10.1200/JCO.2008.17.0472.

Natural killer lymphocytes: biology, development, and function.

Papamichail M, Perez S, Gritzapis A, Baxevanis C Cancer Immunol Immunother. 2003; 53(3):176-86.

PMID: 14685782 PMC: 11034176. DOI: 10.1007/s00262-003-0478-4.

References

Rosenberg S, Lotze M, Muul L, Leitman S, Chang A, Ettinghausen S . Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985; 313(23):1485-92. DOI: 10.1056/NEJM198512053132327. View

Foa R, Caretto P, Fierro M, Bonferroni M, Cardona S, Guarini A . Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol. 1990; 75(1):34-40. DOI: 10.1111/j.1365-2141.1990.tb02613.x. View

Lafreniere R, Rosenberg S . Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985; 45(8):3735-41. View

Champlin R, Ho W, Gale R, Winston D, Selch M, Mitsuyasu R . Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med. 1985; 102(3):285-91. DOI: 10.7326/0003-4819-102-3-285. View

Beran M, Hansson M, Kiessling R . Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood. 1983; 61(3):596-9. View

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

Lim S, Worman C, Jewell A, Goldstone A . Cellular cytotoxic function and potential in acute myelogenous leukaemia. Leuk Res. 1991; 15(7):641-4. DOI: 10.1016/0145-2126(91)90033-p. View

Rosenstein M, Yron I, Kaufmann Y, Rosenberg S . Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984; 44(5):1946-53. View

Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

10.

West W, Tauer K, Yannelli J, Marshall G, Orr D, Thurman G . Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987; 316(15):898-905. DOI: 10.1056/NEJM198704093161502. View

11.

Mule J, Shu S, Schwarz S, Rosenberg S . Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984; 225(4669):1487-9. DOI: 10.1126/science.6332379. View

12.

Lim S, Worman C, Jewell A, Tsakona C, Giles F, Goldstone A . Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias. Cancer Immunol Immunother. 1991; 33(2):133-7. PMC: 11038071. DOI: 10.1007/BF01742542. View

13.

Fletcher M, Goldstein A . Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2. Lymphokine Res. 1987; 6(1):45-57. View

14.

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

15.

Adler A, Chervenick P, Whiteside T, Lotzova E, Herberman R . Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood. 1988; 71(3):709-16. View

16.

Rees J, Gray R, Swirsky D, Hayhoe F . Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet. 1986; 2(8518):1236-41. DOI: 10.1016/s0140-6736(86)92674-7. View

17.

Price G, Brenner M, Prentice H, Hoffbrand A, Newland A . Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts. Br J Cancer. 1987; 55(3):287-90. PMC: 2001744. DOI: 10.1038/bjc.1987.55. View

18.

Gillis S, Smith K . Long term culture of tumour-specific cytotoxic T cells. Nature. 1977; 268(5616):154-6. DOI: 10.1038/268154a0. View

19.

Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Guarini A . Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings. Bone Marrow Transplant. 1990; 6 Suppl 1:98-102. View

20.

Lim S, Callaghan T, Goldstone A . Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. Acta Haematol. 1991; 85(1):49-50. DOI: 10.1159/000204854. View